Simulations Plus

Pro-ficiency is a company that specializes in providing tech-enabled training and compliance solutions specifically designed for clinical trials. It offers a comprehensive suite of services that includes turnkey virtual training simulators and tools for monitoring training and compliance. The company's platform supports clinical trial investigators and site staff by delivering virtual simulation training and human resources compliance services. Additionally, Pro-ficiency creates original content and utilizes predictive analytics to provide real-time data to sponsors, aiding in the identification and mitigation of potential study errors and protocol violations. By streamlining training and compliance processes, Pro-ficiency aims to reduce the time, cost, and risk associated with clinical trials.

Immunetrics, Inc. is a biosimulation company based in Pittsburgh, Pennsylvania, established in 2003. It specializes in developing biological models and innovative tools for mechanistic modeling, particularly in the context of drug discovery and development. The company offers a software platform called Aegis, designed for model developers, along with disease-specific models and component model libraries. Its modeling software facilitates the creation of models, virtual populations, and experiments, enabling in-depth analysis of human diseases and syndromes. Additionally, Immunetrics provides consulting services in mechanistic and statistical modeling, as well as data analysis, aimed at predicting clinical outcomes of therapeutic interventions for various inflammatory and autoimmune diseases at both individual and trial population levels.

Lixoft specializes in the development of modeling and simulation software aimed at enhancing model-based drug development. The company's innovative platform provides user-friendly tools that facilitate population analysis during pre-clinical and clinical trials, as well as in the individualization of treatment. By streamlining the process of sharing and synthesizing information across various stages of drug development, Lixoft seeks to reduce costs and improve the success rates of new pharmaceuticals. Its solutions are designed to bridge gaps within the modeling and simulation community, promoting collaboration and efficiency in research and development efforts.

Founded in 2015, DILIsym Services develops predictive modeling software focused on drug-induced liver injury (DILI) for the pharmaceutical industry. Its flagship product, DILIsym, supports liver safety assessments during clinical drug development and allows users to perform in vitro to in vivo extrapolation, translate preclinical results to clinical trials, and evaluate patient variability's impact on hepatotoxicity predictions.

Cognigen Corporation, established in 1992, specializes in clinical pharmacology and pharmacometric consulting services. The company collaborates with prominent pharmaceutical and biotechnology firms, as well as organizations like the World Health Organization and the U.S. Food and Drug Administration. Cognigen offers a range of services, including clinical trial simulations, exposure-response evaluations, and data management, alongside the creation and documentation of analysis datasets. With a strong emphasis on expertise and meticulous attention to detail, Cognigen has successfully contributed to the development of over 100 drugs, positioning itself as a trusted partner in the pharmaceutical industry.

Bioreason is a privately held company that specializes in developing software research tools for the pharmaceutical and biotechnology sectors. The company has created a knowledge discovery and management system focused on structure-activity relationships, which aids in the classification and analysis of chemical compounds. Bioreason's software facilitates automated reasoning and integrates various data sources, enhancing decision-making processes for researchers. Additionally, it provides support interfaces tailored for chemists and biologists, streamlining their workflows and improving research efficiency.